Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121417 | 0.76 | — | — | |
| SCHEMBL2480934 | 0.76 | — | — | |
| SCHEMBL24673203 | 0.75 | — | — | |
| SCHEMBL27231283 | 0.74 | — | — | |
| SCHEMBL3435157 | 0.74 | — | — | |
| SCHEMBL2067789 | 0.73 | PIK3CD (0.35) | PIK3CDALDH1A1KMT2ACA12CA1 | |
| SCHEMBL10304918 | 0.73 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL9915229 | 0.69 | — | — | |
| SCHEMBL18699675 | 0.68 | — | — | |
| SCHEMBL208196 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608617-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7378447-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20060178438-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (IN) | 2006-08-10 | — | — | US | disclosed |
| EP-1608617-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004094363-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178438-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | PIK3CD 3991/4885ALDH1A1 709/4885LMNA 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.